1. OS4.3 The BReMen trial: Patients with benign meningioma - is rehabilitation really necessary?. (19th September 2018) Authors: Kessler, A F; Krause, K; Al-Shameri, B; Weiland, J; Linsenmann, T; Ernestus, R; Hagemann, C; Löhr, M; Jentschke, E Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii223 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P-713 Prescription determinants of intrauterine devices in different European countries - Results from the real-world safety study EURAS-LCS12. (30th June 2022) Authors: Eggebrecht, L; Bauerfeind, A; Böhnke, T; Hagemann, C; Cellier, C; Lange, J; Heinemann, K Journal: Human reproduction Issue: Volume 37(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P01.045 Adherence to Tumor Treating Fields in patients with high-grade glioma - a single center experience. (19th September 2018) Authors: Kessler, A; Weiland, J; Breun, M; Linsenmann, T; Ernestus, R; Hagemann, C; Löhr, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P01.046 Complete radiological response under treatment with Tumor Treating Fields following subtotal resection in a series of three Glioblastoma patients. (19th September 2018) Authors: Kessler, A; Linsenmann, T; Westermaier, T; Wolber, W; Hagemann, C; Ernestus, R; Löhr, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P01.047 Improving quality of life in glioma patients: platform for exchange of patients' expertise in TTFields practice. (19th September 2018) Authors: Kessler, A; Jentschke, E; Weiland, J; Dufner, V; Lilla, N; Linsenmann, T; Westermaier, T; Hagemann, C; Ernestus, R; Löhr, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P01.050 Circulating MACC1 transcript plasma levels in glioblastoma patients segregate together with prognostic markers and treatment response. (19th September 2018) Authors: Hagemann, C; Neuhaus, N; Dahlmann, M; Kessler, A F; Kobelt, D; Herrmann, P; Eyrich, M; Freitag, B; Freitag, B; Linsenmann, T; Monoranu, C M; Ernestus, R; Löhr, M; Stein, U Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii240 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P04.17 Antigen heterogeneity in glioblastoma cell lines, patient-derived cells, and patients' glioblastoma tissue is an obstacle for CAR-T cell therapy development. (9th September 2021) Authors: Dufner, V; Schulz, E; Monoranu, C; Hudecek, M; Ernestus, R; Hagemann, C; Löhr, M; Nerreter, T Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P04.33 Effects of Tumor Treating Fields (TTFields) on blood brain barrier (BBB) permeability. (19th September 2018) Authors: Kessler, A F; Schaeffer, C; Burek, M; Ruschig, U; Ernestus, R; Löhr, M; Förster, C; Hagemann, C Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii286 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P06.04.B Efficacy of Podoplanin-CAR-T Cells inex vivo Patient Derived Glioblastoma Organoids. (5th September 2022) Authors: Diener, L; Goedert, N; Schulz, T; Monoranu, C; Ernestus, R; Hagemann, C; Löhr, M; Nerreter, T; Dufner, V Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P10.01.A Reversible blood-brain barrier (BBB) disruption by Tumor Treating Fields (TTFields) in a human 3Din vitro model. (5th September 2022) Authors: Salvador, E; Kessler, A F; Köppl, T; Schönhärl, S; Burek, M; Tempel Brami, C; Voloshin, T; Giladi, M; Ernestus, R; Löhr, M; Förster, C; Hagemann, C Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗